The efficacy of the third-generation EGFR-TKI osimertinib has been shown to be superior to that of first-generation TKIs for the first-line treatment of EGFR-mutant advanced NSCLC [25, 26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.